Yi Hong Yao
Chief Tech/Sci/R&D Officer presso CELLULAR BIOMEDICINE GROUP, INC.
Profilo
Yi Hong Yao is currently the Chief Scientific Officer at AbelZeta Pharma, Inc. Prior to this, he worked as a Director at Medimmune, Inc. from 2011 to 2015.
Dr. Yao received his graduate degree from Boston University, his doctorate from the University of Kansas, and his undergraduate degree from Fudan University.
Posizioni attive di Yi Hong Yao
| Società | Posizione | Inizio |
|---|---|---|
| CELLULAR BIOMEDICINE GROUP, INC. | Chief Tech/Sci/R&D Officer | 01/08/2015 |
Precedenti posizioni note di Yi Hong Yao
| Società | Posizione | Fine |
|---|---|---|
| Medimmune, Inc. | Director/Board Member | 01/07/2015 |
Formazione di Yi Hong Yao
| Boston University | Graduate Degree |
| University of Kansas | Doctorate Degree |
| Fudan University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
AbelZeta Pharma, Inc.
 AbelZeta Pharma, Inc. BiotechnologyHealth Technology Cellular Biomedicine Group, Inc. is a holding company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. It specializes in immune cell therapy. The company was founded in 2009 and is headquartered in Rockville, MD. | Health Technology |
| Medimmune, Inc. | Health Technology |
- Borsa valori
- Insiders
- Yi Hong Yao
